Sanofi Reaches Agreement with US Government to Lower Medicine Costs

Sanofi has entered into a voluntary, confidential agreement with the US government aimed at reducing medicine costs for American patients while fostering innovation and US-based biopharmaceutical manufacturing. The agreement, which aligns with President Trump's requests, will enable state Medicaid programs to access certain Sanofi medicines at prices comparable to those in other high-income nations, resulting in an average price reduction of 61 percent for drugs treating conditions like diabetes, cardiovascular diseases, neurological disorders, and cancer. Additionally, consumers will benefit from lower-cost medicines through platforms like TrumpRx.gov, with average savings of nearly 70 percent on certain treatments for infections, cardiovascular, and diabetic conditions. Sanofi commits to aligning Medicaid prices, offering direct patient discounts, implementing a more balanced pricing approach in other high-income economies, and expanding its planned $20 billion investment in US manufacturing. The agreement also provides a three-year tariff-free period for Sanofi's imported products. This initiative is expected to strengthen the US role in scientific research and development without impacting Sanofi's growth strategy or financial outlook.